Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
Objective. We aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Methods. T2DM patients with overweight or obesity who visited the Metabolic...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/4126995 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554765738835968 |
|---|---|
| author | Hao Zhaohu Huang Xiao Shao Hailin He Feng |
| author_facet | Hao Zhaohu Huang Xiao Shao Hailin He Feng |
| author_sort | Hao Zhaohu |
| collection | DOAJ |
| description | Objective. We aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Methods. T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks. Changes in blood glucose and lipid levels, blood pressure, and body weight, as well as the occurrence of hypoglycaemia and other adverse events, were compared. Results. 309 patients completed the study (143 in liraglutide group and 166 in dapagliflozin group). After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from 8.80%±1.41% to 7.02%±1.05%, 10.41±3.13 to 7.59±2.16 mmol/L, and 17.90±4.39 to 10.12±2.47 mmol/L, respectively, in the dapagliflozin group, and from 8.92%±1.49% to 6.78%±1.00%, 10.04±2.99 to 7.20±1.63 mmol/L, and 17.30±4.39 to 10.13±4.15 mmol/L, respectively, in the liraglutide group. Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different. Systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) level significantly decreased from 144.1±19.1 to 139.7±16.2 mmHg (p=0.001) and from 3.21±0.94 to 2.98±0.89 mmol/L (p=0.014), respectively, in the dapagliflozin group. After COVID-19 outbreak, the number of patients taking sleep-promoting drugs increased from 4.9% to 9.4% (p=0.029). Conclusions. Liraglutide and dapagliflozin had strong hypoglycaemic effects in patients with overweight or obesity and T2DM at the beginning of the COVID-19 pandemic. Dapagliflozin may be beneficial in improving SBP and LDL-C levels; however, further research is warranted. |
| format | Article |
| id | doaj-art-bffb1f94fcac4081bc1b7ee07caa13d3 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-bffb1f94fcac4081bc1b7ee07caa13d32025-02-03T05:50:39ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/4126995Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, ChinaHao Zhaohu0Huang Xiao1Shao Hailin2He Feng3Department of Metabolic Disease Management CenterNHC Key Laboratory of Hormones and Development (Tianjin Medical University)Department of Metabolic Disease Management CenterDepartment of CardiologyObjective. We aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Methods. T2DM patients with overweight or obesity who visited the Metabolic Disease Management Center at Tianjin Fourth Central Hospital from October 2019 to January 2020 were recruited and randomised to receive dapagliflozin or liraglutide for 24 weeks. Changes in blood glucose and lipid levels, blood pressure, and body weight, as well as the occurrence of hypoglycaemia and other adverse events, were compared. Results. 309 patients completed the study (143 in liraglutide group and 166 in dapagliflozin group). After 24 weeks, HbA1c, fasting blood glucose (FPG), and 2 h postprandial blood glucose (2hPG) levels significantly decreased from 8.80%±1.41% to 7.02%±1.05%, 10.41±3.13 to 7.59±2.16 mmol/L, and 17.90±4.39 to 10.12±2.47 mmol/L, respectively, in the dapagliflozin group, and from 8.92%±1.49% to 6.78%±1.00%, 10.04±2.99 to 7.20±1.63 mmol/L, and 17.30±4.39 to 10.13±4.15 mmol/L, respectively, in the liraglutide group. Changes in HbA1c, FPG, and 2hPG levels between groups were not significantly different. Systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) level significantly decreased from 144.1±19.1 to 139.7±16.2 mmHg (p=0.001) and from 3.21±0.94 to 2.98±0.89 mmol/L (p=0.014), respectively, in the dapagliflozin group. After COVID-19 outbreak, the number of patients taking sleep-promoting drugs increased from 4.9% to 9.4% (p=0.029). Conclusions. Liraglutide and dapagliflozin had strong hypoglycaemic effects in patients with overweight or obesity and T2DM at the beginning of the COVID-19 pandemic. Dapagliflozin may be beneficial in improving SBP and LDL-C levels; however, further research is warranted.http://dx.doi.org/10.1155/2022/4126995 |
| spellingShingle | Hao Zhaohu Huang Xiao Shao Hailin He Feng Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China Journal of Diabetes Research |
| title | Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China |
| title_full | Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China |
| title_fullStr | Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China |
| title_full_unstemmed | Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China |
| title_short | Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China |
| title_sort | efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus a randomised controlled clinical trial in tianjin china |
| url | http://dx.doi.org/10.1155/2022/4126995 |
| work_keys_str_mv | AT haozhaohu efficacyandsafetyofdapagliflozinversusliraglutideinpatientswithoverweightorobesityandtype2diabetesmellitusarandomisedcontrolledclinicaltrialintianjinchina AT huangxiao efficacyandsafetyofdapagliflozinversusliraglutideinpatientswithoverweightorobesityandtype2diabetesmellitusarandomisedcontrolledclinicaltrialintianjinchina AT shaohailin efficacyandsafetyofdapagliflozinversusliraglutideinpatientswithoverweightorobesityandtype2diabetesmellitusarandomisedcontrolledclinicaltrialintianjinchina AT hefeng efficacyandsafetyofdapagliflozinversusliraglutideinpatientswithoverweightorobesityandtype2diabetesmellitusarandomisedcontrolledclinicaltrialintianjinchina |